BMY-14802

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BMY-14802
BMY-14802 structure.png
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C18H22F2N4O
Molar mass 348.389 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

BMY-14802 is a drug with antipsychotic effects, which acts as both a sigma receptor antagonist, and a 5-HT1A agonist.[1][2][3][4]

References[edit]

  1. ^ Taylor DP, Eison MS, Moon SL, Schlemmer RF, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG (1993). "A role for sigma binding in the antipsychotic profile of BMY 14802?". NIDA Research Monograph. 133: 125–57. PMID 8232511. 
  2. ^ Vanecek SA, Essman WD, Taylor DP, Woods JH (January 1998). "Discriminative stimulus characteristics of BMY 14802 in the pigeon". The Journal of Pharmacology and Experimental Therapeutics. 284 (1): 1–9. PMID 9435153. 
  3. ^ Kitanaka J, Kitanaka N, Tatsuta T, Hall FS, Uhl GR, Tanaka K, Nishiyama N, Morita Y, Takemura M (May 2009). "Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice". Psychopharmacology. 203 (4): 781–92. doi:10.1007/s00213-008-1425-z. PMC 3157915Freely accessible. PMID 19052726. 
  4. ^ Paquette MA, Foley K, Brudney EG, Meshul CK, Johnson SW, Berger SP (July 2009). "The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism". Psychopharmacology. 204 (4): 743–54. doi:10.1007/s00213-009-1505-8. PMC 2845289Freely accessible. PMID 19283364.